Median Technologies (FR0011049824, ALMDT), a leading innovator in the development of artificial intelligence (AI)-powered medical devices for early cancer detection, is set to attend the Radiological Society of North America (RSNA) 2024 Annual Meeting, scheduled to take place in Chicago, IL, USA, from December 1 to December 5, 2024. During the event, Median Technologies will showcase its flagship product, eyonis™, a suite of AI-driven software solutions designed for early cancer diagnostics. The company’s iCRO and eyonis™ teams will be available to meet with attendees at Booth #5442, located in the AI Showcase in South Hall, Level 3, from December 1-4, the technical exhibit dates.
At the event, Median Technologies will highlight the latest advancements related to its eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD). This device, which utilizes AI and machine learning to assist in the early detection of lung cancer, is part of the company’s broader efforts to revolutionize early cancer diagnostics. In addition to presenting updates on eyonis™ LCS, Median will also provide insights into the progress of its iCRO central imaging services, which offer AI-powered oncology trial imaging services to pharmaceutical companies globally.
Key Milestones for eyonis™ LCS
In August 2024, Median Technologies reported significant progress with eyonis™ LCS, announcing that the device met all primary and secondary endpoints with statistical significance in the REALITY study (Clinicaltrials.gov identifier: NCT0657623), the first of two pivotal clinical trials for eyonis™ LCS. This promising outcome was achieved despite the inclusion of numerous challenging Low Dose Computed Tomography (LDCT) images in the study. To further discuss these findings, Median recently held a webinar featuring two prominent U.S. pulmonologists who provided expert commentary on the REALITY data.
Fredrik Brag, CEO of Median Technologies, expressed his excitement about the upcoming RSNA presentation, stating, “We are thrilled to present the eyonis™ LCS data at RSNA. The recently published REALITY study data suggest that eyonis™ LCS has the potential to be a game-changer, significantly improving early lung cancer diagnosis, enabling life-saving interventions, and enhancing the accessibility of broader screening programs. Based on the strength of our data, we are now focused on preparing for marketing authorization filings in both the U.S. and Europe in the first half of 2025, following the completion and data analysis of our second pivotal study, RELIVE, in the first quarter of 2025.”
Presentations and Exhibits at RSNA 2024
During the RSNA Annual Meeting, the eyonis™ team will deliver the following key presentations:
- Scientific Poster Presentation: “Performances of an End-to-End AI/ML CADe/CADx SaMD for Nodule Detection and Characterization in Lung Cancer Screening on an Independent Cohort Compared to Radiologists.”
- Session: Chest Imaging (T2-SPCH-2)
- Scientific Poster Discussion: Tuesday, December 3, 9:00 AM – 9:30 AM CST
- Location: Learning Center, East, Level 3
- Industry Presentation: “New Horizons in the Fight Against Lung Cancer: From Design to Regulatory Filing. Discover How eyonis™ LCS, Median Technologies’ AI-based SaMD, Can Catalyze Lung Cancer Screening Implementation.”
- Session: AI-Theater Presentation (IT5-AI105)
- Presentation Time: Tuesday, December 3, 12:30 PM – 12:50 PM CST
- Location: AI Theater, Booth 5536, South Hall, Level 3
About eyonis™ LCS
eyonis™ Lung Cancer Screening (LCS) is an AI-powered diagnostic tool designed to assist clinicians in detecting lung cancer at its earliest stages, using low-dose computed tomography (LDCT) scans. Early detection of lung cancer is critical, as it is more treatable when diagnosed in its early stages. eyonis™ LCS has been classified by regulatory authorities as Software as a Medical Device (SaMD), and it is undergoing two pivotal clinical studies required for obtaining marketing approvals in both the U.S. and Europe: the completed REALITY study and the ongoing RELIVE study. The company plans to submit its applications for FDA 510(k) premarket clearance and CE marking in 2025, following the completion of these studies and the analysis of the data.
In parallel with its focus on lung cancer, Median Technologies has been actively deploying its AI-driven technology across a variety of cancer indications. Through its iCRO business unit, Median’s AI-based services are being used by pharmaceutical companies to perform medical image analysis and management for oncology clinical trials, contributing to the development of innovative cancer therapeutics.
About the RSNA Annual Meeting
The RSNA Annual Meeting is the world’s largest medical imaging conference, attracting more than 50,000 medical imaging professionals from over 120 countries. The meeting will feature over 300 educational courses and more than 2,800 scientific presentations spanning a wide range of subspecialties in radiology. RSNA 2024 will also host the largest medical equipment exhibition, showcasing products and services from nearly 700 manufacturers, suppliers, and developers, ranging from innovative startups to major industry players.
About Median Technologies
Median Technologies is a pioneer in the development of innovative imaging solutions for cancer diagnostics and treatment. The company’s offerings include eyonis™, an AI-powered suite of Software as a Medical Device (SaMD) solutions, as well as iCRO services, which provide medical image analysis and management for oncology clinical trials. Median’s AI-driven technologies enable biopharmaceutical companies and clinicians to enhance the accuracy of early cancer diagnoses and expedite the development of novel cancer therapies. Headquartered in France, Median Technologies also has a presence in the U.S. and China, and is traded on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Additionally, the company is eligible for the French SME equity savings plan scheme (PEA-PME).
